Xultophy is approved in its first market Switzerland- Novo Nordisk

Novo Nordisk announced Switzerland as the first country to launch Xultophy (IDegLira) for people with Type 2 Diabetes. Xultophy is the first combination of a basal insulin [Tresiba (insulin degludec)] and a GLP-1 analogue [Victoza (liraglutide)]. Xultophy is administered as a once-daily single injection independently of meals. It is intended for use in adults with Type 2 diabetes that are inadequately controlled with oral glucose-lowering treatments when these are used alone or together with basal insulin. For people with Type 2 Diabetes uncontrolled on basal insulin, Xultophy has demonstrated a significant 1.9% HbA1c reduction, mean weight loss of 2.7 kg and a low rate of hypoglycaemia (low blood sugar) comparable to insulin degludec.

Comment: Many patients are concerned about insulin-based therapies due to a fear of weight gain and hypoglycaemia. In the DUAL II trial, Xultophy demonstrated spectacular HbA1c reductions with a weight loss of 2.7 kg for patients uncontrolled on basal insulin.